Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Sales of Investments

Cash received from selling or redeeming investments.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments outflow grows to $506.11K

Q1 FY2026 sales of investments was $506.11K, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $506.11K.

Context

  • Sales of investments amounted to 0.0% of revenue in FY2025.
  • Sales of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $506.11K or moves back toward the trailing-twelve-month quarterly average of $126.53K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$506.11K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$506.11K— YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Sales of Investments vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 sales of investments of $506.11K is the 4th largest of the 9 companies compared; the peer median is $0.
  • Sales of investments amounts to 35.8% of revenue for COEP, versus a peer median of 10.4%.
COEP Competitors Peer median
Sales of Investments for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$143.66M +25.2%——
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$31.29M -56.2%-29.1%20.7%
CUECue Biopharma, Inc.LTM Mar 2026$16.5M —+48.9%50.4%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$506.11K ——35.8%
EQEquillium, Inc.LTM Mar 2026$0 -100.0%-48.6%—
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding COEP) $0-56.2%-29.1%10.4%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.45M)(37.57M)(21.27M)(10.88M)(11.92M)
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
Deferred Income Tax5.34M0000
Stock-Based Compensation1.9M0477.5K1.1M1.22M
Change in Working Capital(2.98M)(550.34K)1.73M(125.26K)(1.46M)
Accounts Receivables21.79K(8.08K)(30.9K)(234.74K)(7.35K)
Inventory(422.02K)0000
Accounts Payables(1.58M)(35.07K)1.32M(149.94K)(381.01K)
Other Working Capital(1M)(507.19K)437.31K259.42K(1.07M)
Other Non-Cash Items4.26M33.25M10.79M2.21M2.34M
Operating Cash Flow(4.49M)(3.88M)(7.24M)(6.65M)(8.6M)
Capital Expenditures(1.75M)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.75M)0000
Debt Repayment(1.62M)(2.42M)(575K)1.2M771.25K
Common Stock Issued10.14M3.27M5.29M100K12.97M
Common Stock Repurchased(247.17K)0000
Dividends Paid00000
Other Financing Activities(50.9K)4.63M200K500K0
Financing Cash Flow8.22M5.49M4.92M5.71M13.74M
Effect of Forex Changes00000
Net Change in Cash1.98M1.61M(2.32M)(936.25K)5.14M
Free Cash Flow(6.24M)(3.88M)(7.24M)(6.65M)(8.6M)

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.